SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
Status:
Completed
Trial end date:
2003-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the
tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining SU5416 with chemotherapy may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of SU5416 and paclitaxel in treating
patients who have recurrent, locally advanced, or metastatic cancer of the head and neck.